Kolomycín (Colistimethate Sodium)

Colistimethate sodium binds to the lipopolysaccharide layer of Gram‑negative bacterial membranes, disrupting membrane integrity and causing leakage of cellular contents, which ultimately leads to bacterial cell death.

The dosage of Kolomycín is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and route of administration. No standard dose is provided here.

The safety of colistimethate sodium in pregnancy and lactation is not well established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Kolomycín, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kolomycín (colistimethate sodium) belongs to the polymyxin class, which is often reserved for multidrug‑resistant Gram‑negative infections when other antibiotics are ineffective. Compared with beta‑lactams or fluoroquinolones, polymyxins have a distinct mechanism but a higher risk of nephro‑ and neuro‑toxicity, requiring careful monitoring.

Kolomycín should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow the packaging label for any additional handling instructions.

Kolomycín is supplied as a sterile solution and can be given by inhalation, intramuscular injection, or intravenous infusion, depending on the clinical indication and physician’s prescription.

The most serious risks include nephrotoxicity, which can lead to acute kidney injury, and neurotoxicity, which may manifest as seizures or altered mental status. Prompt monitoring of renal function and neurological status is essential during therapy.

Kolomycín should be avoided in patients with known hypersensitivity to colistimethate sodium or other polymyxins, and in individuals with severe renal impairment unless dose adjustments are made and close monitoring is ensured.